KORU Medical Systems to Participate in Upcoming Investor Conferences

KORU Medical Systems (NASDAQ: KRMD), a notable player in the medical technology sector, is set to participate in multiple investor conferences in November and December 2025. The company is recognized for its innovative and patient-centric large volume subcutaneous infusion solutions, which aim to enhance the quality of life for patients globally. Management will be present at the 16th Annual Craig-Hallum Alpha Select Conference on November 18, followed by the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20. Additionally, KORU Medical will present at Piper Sandler’s 37th Annual Healthcare Conference on December 2, at 9:30 AM ET. Stakeholders and interested parties can access both live and archived webcasts of these events through the News/Events section on KORU Medical’s website.

KORU Medical develops and markets the Freedom Syringe Infusion System, which includes products like the Freedom60® and FreedomEDGE® Syringe Infusion Drivers, among others. These devices were designed for self-administration by patients at home or under professional supervision in infusion centers. Since the Freedom System’s initial FDA clearance in 1994, it has established a solid reputation in home-based healthcare. Furthermore, KORU Medical supports biopharmaceutical companies through its Pharma Services and Clinical Trials division, offering customized solutions for drug development processes tailored to various medication categories.

For more detailed insights into KORU Medical's offerings, investors can visit their official website, www.korumedical.com. This participation in key conferences underscores KORU Medical's commitment to transparency and engagement with the investment community as it advances its mission in the healthcare landscape.

KORU Medical Systems (NASDAQ: KRMD) presents a compelling opportunity for investors as it gears up to participate in three notable investor conferences: the 16th Annual Craig-Hallum Alpha Select Conference, Canaccord Genuity MedTech Forum, and Piper Sandler’s 37th Annual Healthcare Conference. These events are critical for KORU Medical, providing a platform to showcase its leading innovations in large volume subcutaneous infusion solutions.

The ongoing development and commercialization of the Freedom Syringe Infusion System—a robust offering within KORU’s portfolio—demonstrate the company’s commitment to improving patient care. With products that facilitate self-administration and utilize advanced technology, KORU Medical is well-positioned to continue gaining traction in the healthcare market. The FDA-cleared Freedom System, recognized since 1994, emphasizes the company’s long-standing presence and reliability in the industry.

Investors should focus on KORU's potential growth trajectories, especially in the Pharma Services and Clinical Trials business segment. As biopharmaceutical companies increasingly require efficient infusion solutions for drug development, KORU’s capacity to customize its offerings enhances its relevance and market adaptability.

As KORU Medical showcases its strengths at these upcoming conferences, it presents a prime opportunity for investors to gauge management's insights regarding market trends, competitive positioning, and strategic vision. Positive reception and feedback from these events could lead to upward revisions of the company’s stock price.

Given the increasing demand for patient-centric medical technologies and KORU's innovative solutions, investors should consider KORU Medical as a strategic addition to their portfolios. Monitoring developments from these conferences will be crucial for assessing KORU’s growth prospects and overall market performance. Engaging with the company's communications during these forums can provide valuable insights leading into potential investment decisions.